A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT05006716
Trial Phases:	Phase I Phase II	Protocol IDs:	BGB-16673-101 (primary) NCI-2022-01959 2022-502157-33-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	BeiGene
NCI Full Details:	http://clinicaltrials.gov/show/NCT05006716

Summary

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1
monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety
expansion of selected doses, and a Phase 2 (expansion cohorts)

Treatment Sites in Georgia

City of Hope Atlanta
600 Celebrate Life Parkway
Newnan, GA 30265
770-400-6169
www.cityofhope.org/locations/atlanta/atlanta-cancer-center

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.